Research programme: neuropeptide Y modulators - Lundbeck
Alternative Names: Lu AA33810Latest Information Update: 04 Nov 2017
At a glance
- Originator Lundbeck Research USA
- Class
- Mechanism of Action Neuropeptide Y receptor agonists; Neuropeptide Y receptor antagonists; Neuropeptide Y5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder; Pain; Substance-related disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Substance-related disorders in USA (Parenteral, Injection)